CHALLENGE: The biggest challenge facing Next Science ahead of its IPO was the diminished appetite for IPOs in the second half of 2018. The Board engaged Sefiani to attract a range of Australian investors to commit funds to the IPO and explain Next Science’s wound-healing technology and to build investor awareness and long-term confidence.
STRATEGY: We focused on giving particular emphasis to high-profile initial angel investor, Lang Walker and his involvement and commitment to the business; showcasing Next Science’s ability to “win the war” against superbugs; and engaging with mainstream and online investment publications, whose journalists have influence among investors through social media.
IMPACT: The IPO received higher than anticipated interest for shares from institutional and retail investors, and national media coverage across TV and online publications, including four carefully timed hero pieces in national mainstream newspapers. Next Science videos were viewed more than 2000 times on highly targeted third-party websites.